We regret to inform you that the Phase 1b clinical trial evaluating RTX-134 in patients with phenylketonuria has been discontinued. To learn more about Rubius Therapeutics and its therapeutic areas of focus, please visit: https://www.rubiustx.com/our-pipeline/#therapeutic-areas.
Sincerely, The Patient Advocacy Team at Rubius Therapeutics
Continue to Site
A Red Cell Therapeutic is a red blood cell that has been genetically engineered into a medicine for the potential treatment of cancer and autoimmune diseases.
Red Cell Therapeutics are administered via a short infusion into a vein and infusion time will vary, depending on the dose level.
The Red Cell Therapeutic will be given at the clinical trial center.
If you consent to Rubius Therapeutics contacting you about information related to its Red Cell Therapeutics and clinical trials, please check the boxes below.
We will contact you about your submission